SLC22A1 and hepatocellular carcinoma: It has been recently shown that overall OCT1 (mRNA/protein) levels in tumor tissue detected using RT-QPCR, mRNA-microarray or immunoblotting may serve as a prognostic biomarker for the response to systemic treatment of HCC with this drug [13, 14, 17].